Mavupharma
About:
Non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Website: https://mavupharma.com/
Top Investors: Frazier Healthcare Partners, Alpine BioVentures
Description:
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Total Funding Amount:
$20M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Kirkland, Washington, United States
Founded Date:
2016-01-01
Contact Email:
logo(AT)2x-350x122.png
Founders:
Michael Gallatin
Number of Employees:
11-50
Last Funding Date:
2017-11-29
IPO Status:
Private
Industries:
© 2025 bioDAO.ai